Insulet Co. (NASDAQ:PODD) Shares Purchased by Vontobel Holding Ltd.

Vontobel Holding Ltd. lifted its position in Insulet Co. (NASDAQ:PODD) by 4.3% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 2,423 shares of the medical instruments supplier’s stock after acquiring an additional 100 shares during the quarter. Vontobel Holding Ltd.’s holdings in Insulet were worth $633,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in PODD. QRG Capital Management Inc. bought a new position in shares of Insulet during the third quarter valued at approximately $297,000. Fisher Asset Management LLC lifted its stake in Insulet by 0.9% in the third quarter. Fisher Asset Management LLC now owns 351,100 shares of the medical instruments supplier’s stock valued at $81,719,000 after buying an additional 3,113 shares during the last quarter. Orion Portfolio Solutions LLC lifted its stake in Insulet by 86.2% in the third quarter. Orion Portfolio Solutions LLC now owns 7,826 shares of the medical instruments supplier’s stock valued at $1,822,000 after buying an additional 3,623 shares during the last quarter. Sumitomo Mitsui DS Asset Management Company Ltd lifted its stake in Insulet by 30.1% in the fourth quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 8,395 shares of the medical instruments supplier’s stock valued at $2,192,000 after buying an additional 1,942 shares during the last quarter. Finally, Nomura Asset Management Co. Ltd. lifted its stake in Insulet by 5.7% in the third quarter. Nomura Asset Management Co. Ltd. now owns 153,416 shares of the medical instruments supplier’s stock valued at $35,708,000 after buying an additional 8,301 shares during the last quarter.

Insulet Stock Performance

Shares of PODD stock opened at $283.68 on Thursday. The stock has a market cap of $19.90 billion, a P/E ratio of 48.58, a P/E/G ratio of 3.52 and a beta of 1.23. The company has a debt-to-equity ratio of 1.21, a current ratio of 3.68 and a quick ratio of 2.80. The company has a fifty day moving average price of $272.37 and a two-hundred day moving average price of $246.18. Insulet Co. has a one year low of $160.19 and a one year high of $289.46.

Insider Activity at Insulet

In other Insulet news, EVP Eric Benjamin sold 12,394 shares of the stock in a transaction dated Tuesday, January 21st. The shares were sold at an average price of $280.00, for a total transaction of $3,470,320.00. Following the sale, the executive vice president now directly owns 11,383 shares in the company, valued at $3,187,240. This represents a 52.13 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, CAO Lauren Budden sold 915 shares of the stock in a transaction dated Tuesday, December 10th. The stock was sold at an average price of $275.62, for a total transaction of $252,192.30. Following the sale, the chief accounting officer now owns 5,733 shares in the company, valued at $1,580,129.46. The trade was a 13.76 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.47% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

Several research firms have commented on PODD. JPMorgan Chase & Co. upped their target price on shares of Insulet from $280.00 to $330.00 and gave the stock an “overweight” rating in a research report on Thursday, December 12th. BTIG Research lifted their target price on Insulet from $260.00 to $270.00 and gave the company a “buy” rating in a research note on Friday, November 8th. Barclays lifted their target price on Insulet from $220.00 to $234.00 and gave the company an “equal weight” rating in a research note on Monday, November 11th. Citigroup lifted their target price on Insulet from $283.00 to $310.00 and gave the company a “buy” rating in a research note on Wednesday, December 11th. Finally, Wells Fargo & Company increased their target price on shares of Insulet from $290.00 to $305.00 and gave the company an “overweight” rating in a research report on Wednesday, December 11th. Two analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $277.13.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.